International
A 4th booster with the bivalent Pfizer vaccine, which targets both the omicron BA.4–BA.5 variant and the original COVID-19 strain, generates a higher antibody response against the newer Omicron subvariants than the original Pfizer vaccine, according to international research. The study, which looked at omicron subvariants including XBB.1, found that there were higher antibody responses to the bivalent vaccine whether people had a history of COVID infection or not, although people who had caught COVID-19 in the past generated higher antibody responses overall. The biggest difference between the vaccines was seen in people who hadn't previously caught COVID-19. The authors say the data supports the use of the current bivalent vaccine and underscores the importance of monitoring real-world effectiveness.
From:
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
